# Pulsed Field Ablation for the Treatment of Persistent Atrial Fibrillation: Pulmonary Vein Plus Superior Vena Cava Isolation Versus Pulmonary Vein Isolation Alone-A Prospective, Multicenter, Randomized Controlled Study

Study · id `cardio:ct-nct07819175` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07819175](<https://clinicaltrials.gov/study/NCT07819175>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07819175

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 340 participants.

## Technical summary

Registry record NCT07819175. Randomized; no masking; primary purpose treatment. Start 2026-10-08 (anticipated); primary completion 2028-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 340 participants (planned count; ClinicalTrials.gov record NCT07819175, source copy `cardio:ctgov-nct07819175-2026-09-14`, retrieved 2026-10-26)
- Planned start: 2026-10-08 (anticipated) (ClinicalTrials.gov record NCT07819175, source copy `cardio:ctgov-nct07819175-2026-09-14`, retrieved 2026-10-26)
- Primary completion: 2028-10 (anticipated) (ClinicalTrials.gov record NCT07819175, source copy `cardio:ctgov-nct07819175-2026-09-14`, retrieved 2026-10-26)
- Completion: 2028-10 (anticipated) (ClinicalTrials.gov record NCT07819175, source copy `cardio:ctgov-nct07819175-2026-09-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07819175, source copy `cardio:ctgov-nct07819175-2026-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07819175-2026-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pulsed Field Ablation for the Treatment of Persistent Atrial Fibrillation: Pulmonary Vein Plus Superior Vena Cava Isolation Versus Pulmonary Vein Isolation Alone-A Prospective, Multicenter, Randomized Controlled Study
- Condition: Persistent Atrial Fibrillation
- Intervention (Device): Pulsed Field Ablation - pulmonary vein isolation
- Intervention (Device): Pulsed Field Ablation - Pulmonary Vein Isolation + Superior Vena Cava Isolation
- Lead sponsor: Ruijin Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Ruijin Hospital (`cardio:org-ruijin-hospital`)

## Provenance

Content hash: f0fe777fe032f5a639fcfa43cc465848948329bead3fa127e1f074a92a720702
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
